| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 117.75 | 3650 |
| Intrinsic value (DCF) | 5.90 | 88 |
| Graham-Dodd Method | n/a | |
| Graham Formula | 2562.73 | 81516 |
Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Their lead candidate, TTI-101, is currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).